Ranking Profile - MaxCyte Inc

Introduction

MaxCyte Inc (MaxCyte) discovers, manufactures, and commercializes cell-based medicines. The company’s products include MaxCyte STX, MaxCyte VLX, MaxCyte GT, ExPERTATx, ExPERTGTx, ExPERTSTx and ExPERTVLx scalable transfection systems, which use the flow electroporation technology for engineering of cells. It is investigating MCY-M11 IP, a mesothelin-targeted therapy for treating ovarian and peritoneal mesothelioma; and MCY-M11 IV therapy for undisclosed solid tumors. MaxCyte provides insourcing services such as instrument training, follow-on experimentation and others. The company developed CARMA, a proprietary technology platform for the evolution of chimeric antigen receptor (CAR) immune cell therapies based on non-viral, human messenger RNA (mRNA), and its ExPERT platform facilitates complex cellular engineering to enable the next generation of cellular therapies, which allow molecules to be gently, consistently, and repeatably inserted into cells for specific purposes. Its products are used for designing functional cell-based assays, protein and antibody expression, stable cell line development, viral vector production, gene editing and cell and gene therapies. MaxCyte is headquartered in Rockville, Maryland, the US.